Menu

MicroMedicine to Launch Automated, Microfluidics-based Cell Isolation Technology at the Society for Immunotherapy of Cancer (SITC) Meeting

MicroMedicine, Inc., a life sciences technology company, today announced that it will be launching its patented one-of-a-kind white blood cell isolation technology, the Sorterra™ Cell Isolation System, at the 34th Annual SITC Conference.

Nov 7, 2019
MicroMedicine, Inc.

The conference will be held Nov. 6-10, 2019 in National Harbour, MD and is a highly attended scientific meeting for professionals in the cancer immunotherapy field.

This new automated technology gently and reliably isolates white blood cells from human peripheral blood using microfluidic channels without the use of centrifugation or labeling. This results in more effective and efficient isolation while preserving sample integrity. Sorterra typically yields 30% more lymphocytes compared to density gradient methods, >99.9% red blood cell and platelet removal, and a >98% viability of white blood cells.* Sorterra is intended for use in research and development and clinical research labs. 

"We are very excited to launch this technology at SITC this year," stated Ravi Kapur, PhD, Co-founder and CEO of MicroMedicine.  "Our team has worked meticulously and tirelessly on improving and perfecting the separation process and we're thrilled with the results." Dr. John Powderly, an early adopter of the Sorterra system stated, "The system recovers twice as many cells in half the time, leading to less input blood required to conduct the downstream assays and significant time savings."

MicroMedicine will be available at Booth 205 to discuss Sorterra's performance and usability improvements further. Carolina BioOncology will be at Booth 629.

MicroMedicine's microfluidic technology will also be represented in two posters focused on application data:

"Inertial Microfluidics Enables Highly Consistent Separation and Concentration of Leukocytes from Human Peripheral Blood for Downstream B-Cell and T-Cell Functional Assays". 

And in partnership with Carolina BioOncology Institute:

"Microfluidic-based Cell Separation Method Improves Workflow for Evaluation of Rare Lymphocytes from Cancer Patient Samples"

Poster Viewing Details:

Posters will be on display from 7 a.m. - 8 p.m. on Saturday, Nov. 9th, with the presenting authors in attendance during lunch (12:30 - 2 p.m.)

Poster #1     Poster Board Number: P10

Title: Inertial Microfluidics Enables Highly Consistent Separation and Concentration of Leukocytes from Human Peripheral Blood for Downstream B-Cell and T-Cell Functional Assays

Authors: Sarah M. Mickool; Eric V. Schmidt; Aleksander J. Jonca; Gustavo Arnal; Mary Vincent Larcom; Melanie Scully; Peng Meng Kou; Nitin Kulkarni; Kyle C. Smith

Poster #2     Poster Board Number: P122

Title: Microfluidic-based Cell Separation Method Improves Workflow for Evaluation of Rare Lymphocytes from Cancer Patient Samples

Author: Jodi Stone; Megan E. Nichols; Amy Austin; Kala Bradshaw; Jessica E. Norris; Jennifer Montague; Peng Meng Kou; Nitin Kulkarni; Nirav Sheth; Anya Manning; Sarah M. Mickool; Kyle C. Smith; Ravi Kapur; John D. Powderly


December 2019

Markers of Alzheimer’s

Hints about brain health can be found in the blood

Marketplace

Sponsored Product Updates

Chemyx: Navigating Legal and Regulatory Requirements for Cannabis Research and Product Development in the United States
Chemyx: Navigating Legal and Regulatory Requirements for Cannabis Research and Product Development in the United States
Given its legal status as a controlled substance, researchers, producers, and developers still must be aware of a considerable number of regulatory guidelines and practices governing the cannabis industry.
Chemyx: Cannabis Extraction on the Cutting Edge
Chemyx: Cannabis Extraction on the Cutting Edge
Tully Stroud, Chief Scientific Officer for Elite Molecular Labs, talks about the growing field of cannabis extraction and refinement. 
Heart-on-a-Chip Technology Predicts Preclinical Systolic and Diastolic in vivo Observations for Novel Cardiac Drug in Development
Heart-on-a-Chip Technology Predicts Preclinical Systolic and Diastolic in vivo Observations for Novel Cardiac Drug in Development
TARA Biosystems, Inc. today reported in vivo and in vitro functional data from a study of investigational candidate, MYK-491, showing that TARA’s human iPSC-derived organ-on-a-chip technology can directly measure in vivo cardiac performance.